Archives
-
MG-262: Proteasome Timing in Inflammatory Cells
2026-08-17
MG-262 is a reversible, cell-permeable proteasome inhibitor for dissecting proteostasis, inflammatory signaling, and cell fate. This guide develops a time-resolved assay strategy connecting proteasome blockade with BIRC2/BIRC3 regulation in pulmonary epithelial models.
-
Betaine hydrochloride in Translational Assays
2026-08-17
Betaine hydrochloride provides a water-compatible way to tune enzyme, protease, cell-based, and molecular biology workflows without relying on ethanol. This guide connects practical reagent handling with the TLR4/NF-κB/NLRP3 readouts used in a recent esophageal cancer study while clearly separating established evidence from assay-development recommendations.
-
Autophagy–Metastasis Signature in Colorectal Cancer
2026-08-16
Bai et al. developed a six-gene prognostic signature that integrates autophagy and liver-metastasis biology using bulk and single-cell transcriptomic data in colorectal cancer. The model links higher risk with immune dysfunction, exclusion, macrophage polarization, and CD8+ T-cell exhaustion, providing a framework for risk stratification and hypothesis generation around immunotherapy resistance.
-
Trelagliptin Restores PI-3K/AKT Signaling in Adipocytes
2026-08-15
The reference study links trelagliptin succinate with improved insulin sensitivity in differentiated 3T3-L1 adipocytes through coordinated changes in IRS-1/AKT signaling, GLUT4 membrane localization, glucose uptake, and adipokine secretion. Its main contribution is a cell-level mechanistic framework that extends the interpretation of DPP-4 inhibition beyond glycemic control, while remaining limited by its in vitro design.
-
Protease Inhibitor Cocktail for Protein Extraction
2026-08-14
Protect labile proteins across cell lysis, Western blotting, co-immunoprecipitation, and kinase workflows with a broad-spectrum formulation that also addresses metalloproteases. Its separate EDTA component enables flexible use, but requires deliberate removal before IMAC or two-dimensional electrophoresis.
-
AEBSF.HCl in Protease and Necroptosis Assays
2026-08-14
AEBSF.HCl gives researchers an irreversible way to suppress serine-protease activity in biochemical, cell-lysis, amyloid, and cell-death workflows. Its greatest value in necroptosis studies is as a mechanistic control that helps separate serine-protease effects from lysosomal cathepsin B-driven membrane damage.
-
Calpain Inhibitor I, ALLN: Practical Lab Guide
2026-08-13
Calpain Inhibitor I, ALLN provides a controlled way to inhibit calpain I, calpain II, and selected cathepsins in apoptosis, inflammation research, and ischemia-reperfusion workflows. It should be used as an experimental perturbation with vehicle and pathway controls, not as a diagnostic, therapeutic, or stand-alone proof of calpain-specific mechanism.
-
Esculetin, CKLF1, and Neutrophil Infiltration After Stroke
2026-08-13
The reference study identifies CKLF1-mediated neutrophil recruitment as a mechanism linking post-stroke inflammation with impaired neurological recovery. Using a photothrombotic mouse model, functional MRI, behavioral testing, chemotaxis assays, and CKLF1 knockout experiments, the authors show that esculetin improves recovery while suppressing the CKLF1–CCR5 axis.
-
TPPU and the Liver–Bone Axis in sEH Research
2026-08-12
New evidence connects hepatic soluble epoxide hydrolase activity with osteoclastogenesis through 14,15-EET depletion and suppression of Nrf2 signaling. This thought-leadership perspective examines how TPPU can help translational researchers test that liver–bone mechanism while maintaining appropriate preclinical boundaries.
-
PYR-41: E1 Inhibition and Research Applications
2026-08-12
PYR-41 is an inhibitor of Ubiquitin-Activating Enzyme E1 that disrupts ubiquitin activation, protein turnover, and selected NF-κB responses. Preclinical data support its use in ubiquitination research and a sepsis inflammation model, but off-target activity and limited antiviral validation constrain interpretation.
-
Z-VDVAD-FMK: Mapping Cell-Death Causality
2026-08-11
Z-VDVAD-FMK enables mechanistic dissection of caspase-2-linked apoptosis while exposing the limits of inhibitor-based interpretation. This article connects mitochondrial apoptosis assays with the HOXC8–caspase-1 pyroptosis pathway in NSCLC research.
-
Viral RIPK3 Degradation and Necroptotic Inflammation
2026-08-11
The reference study identifies a family of orthopoxvirus proteins that recruits the SCF ubiquitin-ligase machinery to drive proteasomal degradation of RIPK3, a central necroptosis adaptor. Its genetic and infection models show that vIRD–RIPK3 interactions shape viral replication, inflammation, and disease severity, offering a mechanistic framework for ubiquitin-proteasome pathway research.
-
Batimastat (BB-94): Reliable MMP Assays
2026-08-10
Learn how Batimastat (BB-94), SKU A2577, can improve interpretation of MMP-dependent viability, proliferation, tumor, and neuromuscular-junction experiments. The guide connects quantitative inhibition data with practical handling, controls, storage, and vendor-selection criteria.
-
Asunaprevir: Mechanism, Evidence, and Assay Logic
2026-08-09
Asunaprevir (BMS-650032) is a potent HCV NS3 protease inhibitor, but its greatest research value emerges when biochemical potency, replication data, and cellular controls are interpreted as a connected evidence system. This article develops that framework and uses a chromatin-screening study to clarify how orthogonal assay design can prevent mechanistic overinterpretation.
-
Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO)
2026-08-08
Protease Inhibitor Cocktail (MS-SAFE, 50X in DMSO) helps limit endogenous proteolysis during cell and tissue extraction, with an AEBSF-free formulation intended for mass spectrometry workflows. It is suitable for broad protease control but does not provide standalone metalloproteinase inhibition; separate EDTA supplementation and assay-specific validation are required when those enzymes are relevant.